{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:47:47Z","timestamp":1762174067861,"version":"build-2065373602"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T34IR8095"],"award-info":[{"award-number":["T34IR8095"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY018926","R01EY026574","R01EY019869","R01EY027510","R01EY026574","P30EY022589","R01EY029058"],"award-info":[{"award-number":["R01EY018926","R01EY026574","R01EY019869","R01EY027510","R01EY026574","P30EY022589","R01EY029058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["Unrestricted Grant"],"award-info":[{"award-number":["Unrestricted Grant"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41433-025-04021-8","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:43:59Z","timestamp":1758570239000},"page":"2986-2991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Initial circumpapillary retinal nerve fibre layer rates of change predict glaucomatous progression"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-1921","authenticated-orcid":false,"given":"Vincent Q.","family":"Pham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-6623","authenticated-orcid":false,"given":"Takashi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasan","family":"Moghimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naimul","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Girkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-089X","authenticated-orcid":false,"given":"Massimo A.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Liebmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Zangwill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-3202","authenticated-orcid":false,"given":"Robert N.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"4021_CR1","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"4021_CR2","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","volume":"402","author":"H Jayaram","year":"2023","unstructured":"Jayaram H, Kolko M, Friedman DS, Gazzard G. Glaucoma: now and beyond. Lancet. 2023;402:1788\u2013801.","journal-title":"Lancet"},{"key":"4021_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101160","volume":"97","author":"L Schmetterer","year":"2023","unstructured":"Schmetterer L, Scholl H, Garhofer G, Janeschitz-Kriegl L, Corvi F, Sadda SR, et al. Endpoints for clinical trials in ophthalmology. Prog Retin Eye Res. 2023;97:101160.","journal-title":"Prog Retin Eye Res"},{"key":"4021_CR4","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.ophtha.2017.07.015","volume":"124","author":"AJ Tatham","year":"2017","unstructured":"Tatham AJ, Medeiros FA. Detecting structural progression in glaucoma with optical coherence tomography. Ophthalmology. 2017;124:S57\u2013S65.","journal-title":"Ophthalmology"},{"key":"4021_CR5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/IJG.0000000000002101","volume":"31","author":"B Melchior","year":"2022","unstructured":"Melchior B, De Moraes CG, Paula JS, Cioffi GA, Girkin CA, Fazio MA, et al. Frequency of optical coherence tomography testing to detect progression in glaucoma. J Glaucoma. 2022;31:854\u20139.","journal-title":"J Glaucoma"},{"key":"4021_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/bjo-2022-322470","volume":"108","author":"JH Wu","year":"2024","unstructured":"Wu JH, Moghimi S, Nishida T, Walker E, Kamalipour A, Li E, et al. Evaluation of the long-term variability of macular OCT\/OCTA and visual field parameters. Br J Ophthalmol. 2024;108:211\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4021_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ajo.2021.03.019","volume":"229","author":"SS Swaminathan","year":"2021","unstructured":"Swaminathan SS, Jammal AA, Berchuck SI, Medeiros FA. Rapid initial OCT RNFL thinning is predictive of faster visual field loss during extended follow-up in glaucoma. Am J Ophthalmol. 2021;229:100\u20137.","journal-title":"Am J Ophthalmol"},{"key":"4021_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.ophtha.2014.01.017","volume":"121","author":"A Miki","year":"2014","unstructured":"Miki A, Medeiros FA, Weinreb RN, Jain S, He F, Sharpsten L, et al. Rates of retinal nerve fiber layer thinning in glaucoma suspect eyes. Ophthalmology. 2014;121:1350\u20138.","journal-title":"Ophthalmology"},{"key":"4021_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2016.02.017","volume":"123","author":"M Yu","year":"2016","unstructured":"Yu M, Lin C, Weinreb RN, Lai G, Chiu V, Leung CK. Risk of visual field progression in glaucoma patients with progressive retinal nerve fiber layer thinning: a 5-Year prospective study. Ophthalmology. 2016;123:1201\u201310.","journal-title":"Ophthalmology"},{"key":"4021_CR10","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0161-6420(99)90497-9","volume":"106","author":"MC Leske","year":"1999","unstructured":"Leske MC, Heijl A, Hyman L, Bengtsson B. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106:2144\u201353.","journal-title":"Ophthalmology"},{"key":"4021_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaophthalmol.2014.5319","volume":"133","author":"CP Gracitelli","year":"2015","unstructured":"Gracitelli CP, Abe RY, Tatham AJ, Rosen PN, Zangwill LM, Boer ER, et al. Association between progressive retinal nerve fiber layer loss and longitudinal change in quality of life in glaucoma. JAMA Ophthalmol. 2015;133:384\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"4021_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/archophthalmol.2009.187","volume":"127","author":"PA Sample","year":"2009","unstructured":"Sample PA, Girkin CA, Zangwill LM, Jain S, Racette L, Becerra LM, et al. The African Descent and Glaucoma Evaluation Study (ADAGES): design and baseline data. Arch Ophthalmol. 2009;127:1136\u201345.","journal-title":"Arch Ophthalmol"},{"key":"4021_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/archophthalmol.2010.49","volume":"128","author":"CA Girkin","year":"2010","unstructured":"Girkin CA, Sample PA, Liebmann JM, Jain S, Bowd C, Becerra LM, et al. African Descent and Glaucoma Evaluation Study (ADAGES): II. Ancestry differences in optic disc, retinal nerve fiber layer, and macular structure in healthy subjects. Arch Ophthalmol. 2010;128:541\u201350.","journal-title":"Arch Ophthalmol"},{"key":"4021_CR14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ophtha.2019.03.003","volume":"126","author":"S Moghimi","year":"2019","unstructured":"Moghimi S, Bowd C, Zangwill LM, Penteado RC, Hasenstab K, Hou H, et al. Measurement floors and dynamic ranges of OCT and OCT angiography in glaucoma. Ophthalmology. 2019;126:980\u20138.","journal-title":"Ophthalmology"},{"key":"4021_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ajo.2023.12.002","volume":"260","author":"JH Wu","year":"2024","unstructured":"Wu JH, Moghimi S, Walker E, Nishida T, Brye N, Mahmoudinezhad G, et al. Time to glaucoma progression detection by optical coherence tomography in individuals of African and European descent. Am J Ophthalmol. 2024;260:60\u201369.","journal-title":"Am J Ophthalmol"},{"key":"4021_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/1536867X0600600105","volume":"6","author":"P Royston","year":"2006","unstructured":"Royston P. Explained variation for survival models. Stata J Promot Commun Stat Stata. 2006;6:83\u201396.","journal-title":"Stata J Promot Commun Stat Stata"},{"key":"4021_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2307\/2533118","volume":"53","author":"MS Wulfsohn","year":"1997","unstructured":"Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics. 1997;53:330\u20139.","journal-title":"Biometrics"},{"key":"4021_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ajo.2020.05.019","volume":"222","author":"AA Jammal","year":"2021","unstructured":"Jammal AA, Thompson AC, Mariottoni EB, Urata CN, Estrela T, Berchuck SI, et al. Rates of glaucomatous structural and functional change from a large clinical population: the Duke Glaucoma Registry study. Am J Ophthalmol. 2021;222:238\u201347.","journal-title":"Am J Ophthalmol"},{"key":"4021_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0039-6257(01)00299-5","volume":"47","author":"PG Spry","year":"2002","unstructured":"Spry PG, Johnson CA. Identification of progressive glaucomatous visual field loss. Surv Ophthalmol. 2002;47:158\u201373.","journal-title":"Surv Ophthalmol"},{"key":"4021_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1167\/tvst.7.4.20","volume":"7","author":"Z Wu","year":"2018","unstructured":"Wu Z, Medeiros FA. Comparison of visual field point-wise event-based and global trend-based analysis for detecting glaucomatous progression. Transl Vis Sci Technol. 2018;7:20.","journal-title":"Transl Vis Sci Technol"},{"key":"4021_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ophtha.2023.12.031","volume":"131","author":"FA Medeiros","year":"2024","unstructured":"Medeiros FA, Malek DA, Tseng H, Swaminathan SS, Boland MV, Friedman DS, et al. Short-term detection of fast progressors in Glaucoma: the Fast Progression Assessment through Clustered Evaluation (Fast-PACE) study. Ophthalmology. 2024;131:645\u201357.","journal-title":"Ophthalmology"},{"key":"4021_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ophtha.2022.12.025","volume":"130","author":"FA Medeiros","year":"2023","unstructured":"Medeiros FA, Jammal AA. Validation of rates of mean deviation change as clinically relevant endpoints for glaucoma progression. Ophthalmology. 2023;130:469\u201377.","journal-title":"Ophthalmology"},{"key":"4021_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamaophthalmol.2021.6433","volume":"140","author":"T Nishida","year":"2022","unstructured":"Nishida T, Moghimi S, Wu JH, Chang AC, Diniz-Filho A, Kamalipour A, et al. Association of initial optical coherence tomography angiography vessel density loss with faster visual field loss in glaucoma. JAMA Ophthalmol. 2022;140:319\u201326.","journal-title":"JAMA Ophthalmol"},{"key":"4021_CR24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jamaophthalmol.2024.0906","volume":"142","author":"N Tansuebchueasai","year":"2024","unstructured":"Tansuebchueasai N, Nishida T, Moghimi S, Wu JH, Mahmoudinezhad G, Gunasegaran G, et al. Rate of initial optic nerve head capillary density loss and risk of visual field progression. JAMA Ophthalmol. 2024;142:530\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"4021_CR25","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1167\/iovs.12-9476","volume":"53","author":"DP Crabb","year":"2012","unstructured":"Crabb DP, Garway-Heath DF. Intervals between visual field tests when monitoring the glaucomatous patient: wait-and-see approach. Invest Ophthalmol Vis Sci. 2012;53:2770\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4021_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2022.07.025","volume":"130","author":"C Bradley","year":"2023","unstructured":"Bradley C, Hou K, Herbert P, Unberath M, Boland MV, Ramulu P, et al. Evidence-based guidelines for the number of peripapillary OCT scans needed to detect glaucoma worsening. Ophthalmology. 2023;130:39\u201347.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04021-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04021-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04021-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:07:05Z","timestamp":1762171625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04021-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4021"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04021-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TN is a consultant of Topcon. SM reported grants from the National Eye Institute and University of California Tobacco-Related Disease Research Program. CAG reported grants from the National Eye Institute, EyeSight Foundation of Alabama, and Research to Prevent Blindness, and nonfinancial support from Heidelberg Engineering and Topcon. CAG is a consultant of Iridex and Topcon. MAF reported grants from the National Eye Institute, Research to Prevent Blindness, and Wolfram Research, and nonfinancial support Heidelberg Engineering and Topcon. JML is a consultant of Alcon, Abbvie, AdvanceSight, Carl Zeiss Meditech, Genentech, and Thea. JML reported grants and financial support from Novartis, Research to Prevent Blindness, National Eye Institute, and Research to Prevent Blindness. LZ reported grants from the National Eye Institute; grants from Heidelberg Engineering and nonfinancial support from Carl Zeiss Meditec, Optovue, Heidelberg Engineering, and Topcon. Consultant of Abbvie, AISight Health and Topcon and patents from Carl Zeiss Meditec. RNW is a consultant of Abbvie, Alcon, Amydis, Eyenovia, Iantrek, Implandata, Spinogenix, Toku and Topcon. RNW reported nonfinancial support from Heidelberg Engineering, Carl Zeiss Meditec, Konan Medical, Optovue, Centervue, and Topcon; grants from the National Eye Institute and National Institute of Minority Health Disparities, patents from Toromedes, Carl Zeiss Meditec to UCSD; all outside the submitted work. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}